
    
      This is a multicenter, open-label Phase 1b/2 study in participants with metastatic colorectal
      cancer that will assess the efficacy of etrumadenant.

      Approximately 250 participants will be enrolled to 1 of 3 cohorts:

      Cohort A) etrumadenant + zimberelimab +mFOLFOX-6 +/-bev vs mFOLFOX-6 +/-Bev

      Cohort B) etrumadenant + zimberelimab +mFOLFOX-6 +/-bev vs regorafenib

      Cohort C) chemotherapy-free combinations of etrumadenant + zimberelimab + other agents

      The primary objective of this clinical study is to evaluate the safety of etrumadenant-based
      combination therapy in participants with metastatic colorectal cancer.
    
  